Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Open in API
Filings indexed 986 across all filing types
Latest filing 2015-09-11 Director's Dealing
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
FORM 4 -
Director's Dealing
2015-09-11 English
FORM 4 -
Director's Dealing
2015-09-10 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 27, 2015. The content specifically reports the departure of a Chief Commercial Officer, David Harding, effective August 28, 2015. This corresponds to an announcement of changes in the company's board of directors or senior management. The document is short (2521 characters) and focuses solely on management changes without financial data or other report content. Therefore, it fits the category of Board/Management Information (MANG).
2015-08-27 English
FORM 4 -
Director's Dealing
2015-08-25 English
10-Q
Interim / Quarterly Report Q2 2015
2015-08-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 10, 2015, reporting the company's financial results for the quarter ended June 30, 2015. It specifically mentions that the full text of the press release announcing these results is furnished as an exhibit (Exhibit 99.1). The document itself is short (3324 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the rules, such a document is classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results with key highlights, not a full interim report or annual report. The presence of a press release as an exhibit further supports this classification.
2015-08-10 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.